Back to Agenda
SESSION 3
Session Chair(s)
Toshiyoshi Tominaga, PhD
Project Professor
Keio University Hospital, Japan
Session 3
Speaker(s)
Panel Discussion
Pär Tellner, MPharm, MSc, RPh
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium
Director, Regulatory, Drug development and Manufacturing
![Steven Teerenstra, PhD, MSc](/_Images/member/Generic_Image_Missing-Profile.jpg)
E9 Improving Planning, Conduct, Analysis and Interpretation of Clinical Trials
Steven Teerenstra, PhD, MSc
Medicines Evaluation Board, Netherlands
Statistician
![Corina Dana Dota, MD](/_Images/member/Generic_Image_Missing-Profile.jpg)
E14 Clinical Evaluation of QT/QTc
Corina Dana Dota, MD
AstraZeneca R&D Molndal, Sweden
AZ ECG Centre Director
M4E (CTD) Benefit-Risk Information
Filip Mussen, PhD
Janssen R&D, Pharmaceutical Companies of Johnson & Johnson, Belgium
Vice President, Regional Regulatory Affairs
Panel Discussion
Tomas Salmonson, DrMed, PhD
Critical Path Institute, United States
Partner
Have an account?